NUZ 0.00% 20.0¢ neurizon therapeutics limited

Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-104

  1. 2,686 Posts.
    lightbulb Created with Sketch. 1608
    Hi All,
    Just a few comments on the Morgans paper.

    1. The 14% chance of Phase 2/3 being successful appears to be based on the average amount of P1 trials that go on to be approved. In the case of MPL, the P1 also measured efficacy and not just safety as is normally the case. Additionally the OLE program appears to be supporting [Yet to be proven beyond doubt] the impressive efficacy shown in the P1 MEND trial. I think we can raise that to somewhere above 50%, don't forget Efficacy could drop and still result in FDA approval.
    2. The projected share price of $3.21 following a successful P2/3 is only based on ALS/MND, which is one of the less common conditions where MPL may be of use. E.g Alzheimer, Parkinsons and Huntington's.

    Exciting times


    Cheers
 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
(20min delay)
Last
20.0¢
Change
0.000(0.00%)
Mkt cap ! $97.32M
Open High Low Value Volume
20.5¢ 20.5¢ 20.0¢ $56.77K 280.8K

Buyers (Bids)

No. Vol. Price($)
10 401728 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 52780 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.